{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-066924","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.236217+00:00","generated_at":"2026-05-22T05:35:34.211310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Tyra Biosciences Q1 net loss $28.1M; cash $318.9M; BEACH301 achondroplasia study open","bullets":["Net loss $28.1M vs $18.2M in Q1 2024; R&D expense $25.0M (up 45% YoY) driven by clinical start-up costs.","Cash, equivalents, and marketable securities $318.9M as of March 31, 2025; runway through at least 2027.","BEACH301 Phase 2 study of TYRA-300 for pediatric achondroplasia now enrolling safety sentinel cohort.","SURF431 Phase 1 study of TYRA-430 (FGFR4/3 inhibitor) in HCC initiated; first patient dosed.","SURF302 Phase 2 NMIBC study of TYRA-300 expected to dose first patient in Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-066924","json":"https://secwatch.observer/filing/0000950170-25-066924.json","markdown":"https://secwatch.observer/filing/0000950170-25-066924.md","text":"https://secwatch.observer/filing/0000950170-25-066924.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025066924/0000950170-25-066924-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025066924/tyra-20250508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T05:35:34.211310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}